%0 Journal Article
%A Torres-Cornejo, A.
%A BenMarzouk-Hidalgo, O. J.
%A Viciana, P.
%A Sanchez, B.
%A Lopez-Ruz, M. A.
%A Lopez-Cortes, L. F.
%A Gutierrez-Valencia, A.
%T Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract
%D 2016
%@ 1198-743X
%U http://hdl.handle.net/10668/18746
%X Cross-sectional study comparing seminal human immunodeficiency virus type 1 (HIV-1) shedding in patients receiving boosted protease inhibitor monotherapy (mtPI/rtv) (n = 66) versus triple therapy (TT) (n = 61). Seminal HIV-1 shedding rates in patients with undetectable plasma HIV-RNA were 16.0% on mtPI/rtv compared with 28.6% on TT (p 0.173). Aviraemic status and time on viral suppression were independently associated with lack of seminal HIV-1 shedding. During TT, non PI/rtv-based regimens were associated with a better control of HIV infection in semen despite similar time on viral suppression. The use of mtPI/rtv in well-controlled patients is not associated with increased seminal HIV excretion compared with TT. (C)2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
%K Human immunodeficiency virus 1 infection
%K human immunodeficiency virus 1 treatment
%K male genital tract
%K protease inhibitor monotherapy
%K triple therapy
%K Viral load
%K Blood-plasma
%K Hiv-1 rna
%K Semen
%K Lopinavir/ritonavir
%K Men
%K Ritonavir
%~